title: New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?
authors.affiliation: Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Delhi, India.
authors.forename: Pankaj Kumar
authors.initials: PK
authors.lastname: Garg
authors.affiliation: Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Delhi, India.
authors.forename: Bhupendra Kumar
authors.initials: BK
authors.lastname: Jain
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D016361:Bankruptcy; D003362:Cost-Benefit Analysis; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010817:Physician-Patient Relations; D011788:Quality of Life; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab